
-
Ovid Therapeutics NasdaqGS:OVID Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Location: 441 Ninth Avenue, New York, NY, 10001, United States | Website: https://www.ovidrx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-7.169M
Cash
43.0M
Avg Qtr Burn
-12.39M
Short % of Float
3.24%
Insider Ownership
16.31%
Institutional Own.
55.98%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Soticlestat (OV935) Details Rare genetic disease, Rare diseases, Dravet syndrome, Lennox-Gastaut syndrome | Phase 3 Update | |
OV888 (GV101) Details Cerebral cavernous malformation | Phase 2 Initiation | |
OV329 (GABA-AT inhibitor) Details Epilepsy | Phase 1 Data readout | |
OV935 (CH24H Inhibitor) Details Rare diseases, Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, Rare genetic disease | Failed Discontinued | |
OV101 (δ-selective GABAA receptor agonist) (gaboxadol) Details Genetic disorder, Rare genetic disease, Angelman Syndrome | Failed Discontinued | |
OV101 (gaboxadol) Details Rare genetic disease, Fragile X syndrome | Failed Discontinued |